Below is an
excerpt on how fluorescent light can effect those with Lupus. All
hospital facility managers should be aware of this.
light activates the immunomodulator cis-urocanic acid in vitro:
implications for patients with systemic lupus erythematosus.
McGrath H Jr, Bell JM, Haycock JW. Department of Medicine, Louisiana
State University Medical Center, New Orleans 70112.
OBJECTIVE--Erythemagenic (295-305 nm) ultraviolet-B (UVB) radiation
is toxic to patients with systemic lupus erythematosus (SLE). Cool
white fluorescent lamp emissions produce a similar toxicity even
though the UVB radiation emitted is primarily at the relatively
non-erythemagenic wavelength of 313 nm. The purpose of this study
was to determine if fluorescent light, presumably acting predominantly
along the 313 nm wavelength, exhibits photochemical activity sufficient
to account for toxicity. METHODS--The photochemical activity of
fluorescent light was assessed by testing its capacity to activate
urocanic acid, a plentiful and potent epidermal immunological mediator
normally activated by polychromatic UVB radiation but activated
maximally at 313 nm. Irradiation-induced isomerisation of trans-urocanic
to cis-urocanic acid was quantitated by UV spectroscopy after separation
of the isomers by high performance liquid chromatography.
RESULTS--Fluorescent light irradiation of solutions containing
the photoreceptor trans-urocanic acid produced a cumulative conversion
of trans-to-cis-urocanic acid. This photochemical activity was compared
with that of erythemagenic sunlamps, high in polychromatic UVB emissions.
When normalised for UVB irradiance, the accumulation of cis-urocanic
acid produced by both light sources was essentially equivalent.
Conventional acrylic diffusers that absorb UVB emissions eliminated
the fluorescent light-induced reaction. CONCLUSION--The results
indicate that radiation from fluorescent lamps possesses substantial
photoimmunological capability, sufficient to activate a potent,
potentially dangerous, disease-modifying, immunomodulatory pathway
and that poorly erythemagenic, primarily monochromatic UVB photons
PMID: 8037497 [PubMed - indexed for MEDLINE]
An Open Trial of Morning Light Therapy For Treatment
of Antepartum Depression
Dan A. Oren, M.D., Katherine L. Wisner, M.D., Margaret
Spinelli, M.D., C. Neill Epperson, M.D., Kathleen S. Peindl, Ph.D.,
Jiuan Su Terman, Ph.D., and Michael Terman, Ph.D. Am J Psychiatry
159:666-669, April 2002.
OBJECTIVE: About 5% of pregnant women meet criteria
for major depression. No pharmacotherapy is specifically approved
for antepartum depression; novel treatment approaches may be welcome.
The authors explored the use of morning bright light therapy for
METHOD: An open trial of bright light therapy in
an A-B-A design was conducted for 3-5 weeks in 16 pregnant patients
with major depression. The Hamilton Depression Rating Scale, Seasonal
Affective Disorders Version, was administered to assess changes
in mood. A follow-up questionnaire was used to assess outcome after
RESULTS: After 3 weeks of treatment, mean depression
ratings improved by 49%. Benefits were seen through 5 weeks of treatment.
There was no evidence of adverse effects of light therapy on pregnancy.
CONCLUSIONS: These data provide evidence that morning
light therapy has an antidepressant effect during pregnancy. A randomized
controlled trial is warranted to test this alternative to medication.
other pertinent topics, see left navigation bar and view topics
Joy of Seeing Colors!
Color for Professionals
Does Light Go Beyond Vision?
Our Bulbs and Glare
Our Bulbs and UV Radiation
Children and Light
Seniors and Light
Light and Animals
The Secret of Color Correct Lights
Seeing Better with Optically Treated
© 1999-2003 CRS Light